Verici Dx plc
("Verici Dx" or the "Company")
Result of Annual General Meeting
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the Annual General Meeting ("AGM") held yesterday, all resolutions were duly passed.
The voting results of the AGM were as follows:
|
In Favour |
Against |
Withheld |
|||
|
Resolution |
Votes |
% |
Votes |
% |
Votes |
|
1 |
469,065,903 |
99.98 |
88,290 |
0.02 |
24,006 |
|
2 |
468,421,915 |
99.85 |
718,633 |
0.15 |
37,651 |
|
3 |
469,047,227 |
99.98 |
106,783 |
0.02 |
24,189 |
|
4 |
469,057,547 |
100.00 |
21,408 |
0.00 |
99,244 |
|
5 |
468,889,463 |
99.96 |
189,044 |
0.04 |
99,692 |
|
Verici Dx plc |
||
|
Sara Barrington, CEO |
Via Walbrook PR |
|
|
Singer Capital Markets (Nominated adviser, Joint Broker and Joint Bookrunner) |
Tel: +44 (0)20 7496 3000 |
|
|
Phil Davies / Sam Butcher |
||
|
Oberon Capital (Joint Broker and Joint Bookrunner) |
Tel: +44 (0)20 3179 0500 |
|
|
Mike Seabrook / Adam Pollock / Jessica Cave |
||
|
Walbrook PR (Media & Investor Relations) |
Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
|
|
Alice Woodings / Paul McManus |
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 |
|
|
|
||
